Recent Updates
Recently added Catalysts
SVRA Negative Sentiment Score: 25/100

Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SVRA

Key Takeaway: Savara Inc. is embroiled in a class action lawsuit for alleged securities law violations, specifically related to false and misleading statements regarding their Biologics License Application for MOLBREEVI. Shareholders who purchased shares between March 7, 2024, and May 23, 2025, are encouraged to participate in the suit, as key information regarding chemistry and manufacturing was reportedly inadequate. The deadline for participation is November 10, 2025, and no fees are required to be involved in the lawsuit. This development indicates significant risks for Savara's credibility and operational transparency.

Market Sentiment Analysis

CONCERNS & RISKS

  • Savara Inc. is facing a class action lawsuit for securities law violations.
  • Allegations include making false and misleading statements regarding their BLA for MOLBREEVI.
  • Inadequate information was provided to the FDA, potentially leading to non-approval of the drug.
  • The lawsuit indicates that company's public statements were materially misleading during the class period.

Full Press Release Details

LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 7, 2024 to May 23, 2025
DEADLINE: November 10, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Savara provided inadequate information in the BLA for MOLBREEVI that it submitted to the FDA, specifically failing to provide details on chemistry and manufacturing. The FDA was unlike to approve the Company’s BLA due to these deficiencies. Based on these facts, Savara’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What is the class action lawsuit against Savara Inc. about?

The lawsuit claims Savara made false statements and provided inadequate BLA information to the FDA.

What are the dates for the Savara class period?

The class period runs from March 7, 2024, to May 23, 2025.

What is the deadline to join the lawsuit against Savara?

The deadline to join the lawsuit is November 10, 2025.

Do shareholders need to be lead plaintiffs to recover losses?

No, being a lead plaintiff is not required to participate in recovery.

What assistance does DJS Law Group provide to shareholders?

DJS Law Group offers portfolio monitoring and updates to registered shareholders.

Last updated: Oct 28, 2025